AURA

Aura Biosciences, Inc.

Healthcare
Biotechnology
$653M market cap

Forecast run · Oct 29, 2026Upside rank 1687 of 3,186

Model Signal

ForecastQ Daily Probabilities

24.3%

57.4%

11.7%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$6.30

Price target$17.50

Implied move+177.8%

Analysts8

ForecastQ Portfolios

AURA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.